Soft tissue sarcomas are cancers that develop in your body’s soft tissues like muscle, fat, tendons, or cartilage. Your legs are the most common place they develop. The American Cancer Society ...

Soft tissue sarcomas are rare solid tumors that are being increasingly classified and treated by subtype. Approximately 12,020 people will be diagnosed with a soft tissue sarcoma in the United States ...

Soft tissue sarcomas (STS) represent a heterogeneous group of extraskeletal mesenchymal tumors that affect individuals throughout the entire age continuum. Despite this pervasive influence, key ...

When surgery is part of the treatment plan, choosing a team with deep sarcoma-specific surgical experience is one of the most important decisions a patient can make. With more than 70 distinct sarcoma ...

An oral combination treatment may prevent the progression of advanced leiomyosarcoma, one of the most common subtypes of soft ...

Novel biomarkers like GDF15 and OPN show promise in diagnosing and prognosticating uterine sarcoma, potentially enabling early identification and tailored therapy. Blood-based markers such as NLR and ...

Eftilagimod alfa and Keytruda with radiotherapy improved tumor hyalinization/fibrosis rates in resectable soft tissue sarcoma, surpassing the trial's primary endpoint. The combination therapy achieved ...

A recent analysis reveals that the incidence rates of soft tissue sarcomas - cancers in muscle, fat, blood vessels, nerves, and tendons - are lower in young U.S. active-duty military servicemen ...

Prognostic factors in soft tissue sarcomas encompass a diverse spectrum of clinical, pathological and host-related parameters that influence patient outcomes. Increasingly, research is demonstrating ...

Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline Orphan designation expands LP-284's potential for an estimated ~96,000 global annual soft ...